CANBRIDGE PHARM.DL-00001 Net Asset Momentum
CANBRIDGE PHARM.DL-00001 net asset momentum. CANBRIDGE PHARM.DL-00001 (MF1) recorded a net asset momentum of 28.0% as of December 2025, with net assets of €-341.75 Million EUR. Net Asset Momentum measures the year-over-year percentage change in net assets (total assets minus total liabilities), indicating how rapidly the company is building or eroding its equity base. Explore CANBRIDGE PHARM.DL-00001 cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
YoY Momentum
Current Net Assets
Years of Data
Country
Net Asset Momentum of CANBRIDGE PHARM.DL-00001 (2021–2025)
Net asset momentum of CANBRIDGE PHARM.DL-00001 from 2021 to 2025. This chart tracks CANBRIDGE PHARM.DL-00001's year-over-year net asset growth across 5 annual reporting periods from 2021 to 2025. The most recent momentum reading is +28.0%, with net assets of €-341.75 Million EUR as of December 2025. See net assets of CANBRIDGE PHARM.DL-00001 for net asset value and shareholders' equity analysis.
CANBRIDGE PHARM.DL-00001 Net Asset Momentum by Year (2021–2025)
CANBRIDGE PHARM.DL-00001 net asset momentum by year from 2021 to 2025. The table below shows the complete annual net asset history for CANBRIDGE PHARM.DL-00001 from 2021 to 2025, covering 5 yearly periods. Each row includes total assets, total liabilities, net assets, and the year-over-year momentum figure for that period. For live market cap and overall valuation, see market value of CANBRIDGE PHARM.DL-00001.
| Year | Net Assets (EUR) | Total Assets | Total Liabilities | YoY Momentum |
|---|---|---|---|---|
| 2025 | €-341.75 Million | €165.39 Million | €507.15 Million | ▲ +28.0% |
| 2024 | €-474.49 Million | €116.81 Million | €591.30 Million | ▼ -1092.5% |
| 2023 | €-39.79 Million | €395.36 Million | €435.15 Million | ▼ -112.9% |
| 2022 | €308.56 Million | €702.04 Million | €393.49 Million | ▼ -55.5% |
| 2021 | €693.39 Million | €892.52 Million | €199.13 Million | — |